This phase I/II trial studies the side effects and the best dose of methoxyamine when given together with cisplatin and pemetrexed disodium and to see how well it works in treating patients with solid tumors or mesothelioma that have spread to other places in the body and usually cannot be cured or controlled with standard treatment (advanced), or mesothelioma that does not respond to pemetrexed disodium and cisplatin or carboplatin (refractory). Methoxyamine may shrink the tumor and may also help cisplatin and pemetrexed disodium work better by making tumor cells more sensitive to the drugs. Drugs used in chemotherapy, such as cisplatin and pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving methoxyamine together with cisplatin and pemetrexed disodium may be a better treatment for solid tumors or mesothelioma than methoxyamine and pemetrexed disodium.
Full Archive
How the Immune System is Affected by Pleural Mesothelioma
A recent study looked at the body’s immune system and how it responds to pleural mesothelioma, a cancer of the lining of the lungs. Results were published in the journal Pathobiology. The immune cells around the tumor area of 60 pleural mesothelioma patients were studied. The researchers used biomarkers to[…]
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Primary Outcome Measures Number of participants treated with Alintegimod monotherapy with treatment related adverse events as assessed by CTCAEv5.0 Number of participants treated with Alintegimod in combination with treatment related adverse events as assessed by CTCAEv5.0 Define RPTDs for Alintegimod Secondary Outcome Measures Characterize Pharmacokinetics of Alintegimod monotherapy by measuring[…]
Mesothelioma’s Effects on Mental Health
Mesothelioma is a tough cancer to live with that is incurable and caused by asbestos. A recent study published in the European Journal of Oncology Nursing looked at the impact of mesothelioma on mental health and wellbeing. The frequency of mental health conditions among patients and caregivers was also examined.[…]
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens.
Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study near completion of the Phase 1b
Exposure to Asbestos With BAP1 Mutation Increases Risk of Mesothelioma
In a study presented today at the American Association for Cancer Research Annual Meeting 2024, researchers at Fox Chase Cancer Center showed that mice with a BAP1 germline mutation, after exposure to small levels of asbestos, had a greater chance of developing malignant mesothelioma. The study is being published in[…]
Researchers Looked at Fibroblasts to Determine Their Role in Mesothelioma Growth
Malignant mesothelioma is a hard cancer to treat and is mainly caused by asbestos. It was widely used in construction, steel mills, and other industries. Mesothelioma is especially hard to treat because it grows and spreads quickly. There are unfortunately not many options for the treatment of mesothelioma. It takes[…]
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
This is a first in human (FIH) 2-part study using ACTM-838 in patients with advanced solid tumors resistant to standard of care treatment. Part 1a will evaluate dose escalation and Part 1b will evaluate dose expansion.
Targeting uPARAP Could Improve Mesothelioma Treatment
Mesothelioma is a hard cancer to treat that has low survival rates. This makes it a problem for doctors and researchers. A new study is looking to change this by looking at the collagen receptor uPARAP. The current clinical trial is looking at uPARAP, a protein that is found in[…]
Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma (PENINSULA)
In this Phase-II study, the investigators will investigate the efficacy and safety of lenvatinib in combination with pembrolizumab and chemotherapy in patients with malignant pleural mesothelioma.
